Expression of the activation antigen CD69 predicts functionality ofin vitroexpanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients
- 1 October 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 114 (1) , 66-72
- https://doi.org/10.1046/j.1365-2249.1998.00685.x
Abstract
Gene therapy for AIDS necessitates harvest and expansion of PBMC from HIV-infected patients. We expanded PBMC from healthy blood donors and HIV-infected patients for up to 14 days using four expansion protocols: 3 days of phytohaemagglutinin (PHA) stimulation, continuous PHA stimulation, 3 days of stimulation with anti-CD3 and anti-CD28, and continuous stimulation with anti-CD3 and anti-CD28. Functionality of PBMC was evaluated prior to and after expansion using standard proliferation assay. Phenotype and lymphocyte subset activation defined by expression of CD69 and CD25 were determined using flow cytometry. PBMC from healthy donors and HIV-infected patients were readily expanded. The best expansion was obtained using stimulation for 3 days. After expansion, functionality of PBMC measured as proliferative response was partly conserved. PBMC expanded with stimulation for 3 days exhibited more preserved functionality than PBMC stimulated continuously (P < 0.03). The mean proliferative response in each of the four different expansion protocols correlated with the mean values of CD69 expression. The proliferative responses from patients and healthy donors expanded with PHA stimulation for 3 days correlated with CD69 expression on CD4 cells (r = 0.68, P < 0.01) and on CD8 cells (r = 0.59, P < 0.03). Furthermore, expression of CD69 reliably predicted which patients and donors had highly conserved functionality after in vitro expansion. Finally, PBMC expanded with PHA stimulation for 3 days were examined for apoptosis. Only a minor fraction was primed for apoptosis, and this fraction could be significantly reduced by addition of IL-2 to the culture medium (P < 0.05). In conclusion, the feasibility of expanding PBMC from HIV patients was demonstrated. Expanded PBMC had conserved functionality. Finally, after in vitro expansion, expression of the activation antigen CD69 reliably predicted functionality of PBMC.Keywords
This publication has 29 references indexed in Scilit:
- The Serotonin Analogue Buspirone Increases the Function of PBMC from HIV-infected Individuals In VitroScandinavian Journal of Infectious Diseases, 1997
- A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T Lymphocytes in HIV-Infected Identical Twins. National Institutes of Health, Bethesda, MarylandHuman Gene Therapy, 1996
- Expression of CD69 after In Vitro Stimulation: A Rapid Method for Quantitating Impaired Lymphocyte Responses in HIV-Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Ex Vivo Expansion of CD4 Lymphocytes from Human Immunodeficiency Virus Type 1-Infected Persons in the Presence of Combination Antiretroviral AgentsThe Journal of Infectious Diseases, 1995
- Rapid flow cytometric method for measuring lymphocyte subset activationCytometry, 1995
- A Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-infected Identical TwinsHuman Gene Therapy, 1993
- Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors.The Journal of Experimental Medicine, 1993
- Relationship between IL-2 receptor expression and proliferative responses in lymphocytes from HIV-1 seropositive homosexual menClinical and Experimental Immunology, 1993
- Multiparametric Flow Cytometric Analysis of the Kinetics of Surface Molecule Expression after Polyclonal Activation of Human Peripheral Blood T LymphocytesScandinavian Journal of Immunology, 1992
- Transient expression of interleukin 2 receptors. Consequences for T cell growth.The Journal of Experimental Medicine, 1983